Drug or intervention
Denosumab Clinical Trials
Studies that test Denosumab, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 47Postmenopausal Osteoporosis
Romosozumab and Denosumab Combination Therapy for Osteoporosis
In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.
- Trial name
- NCT07909304
- Testing
- Romosozumab, Romosozumab and Denosumab
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Type 1 Diabetes
Denosumab for Type 1 Diabetes
Type 1 diabetes (T1D) arises from abnormal immune cell-mediated injury to beta cells that make insulin. The injured beta cells can then no longer make the needed amount of insulin to stay healthy.
- Trial name
- NCT06524960
- Testing
- Denosumab
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- City of Hope Medical Center
Knee Osteoarthritis
Cartilage Biomarker Response to Acute Mechanical Loading in Women With Knee Osteoarthritis: Comparison by Antiresorptive Treatment Status
This study evaluates how acute mechanical loading affects cartilage degradation biomarkers in postmenopausal women with mild-to-moderate knee osteoarthritis.
- Trial name
- NCT07881861
- Where
- Turkey (Türkiye)
- Volunteers
- 105 people
- Sponsor
- Sisli Hamidiye Etfal Training and Research Hospital
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
- Trial name
- NCT06374459
- Testing
- Zumsemetinib, Capecitabine, Zoledronic acid
- Where
- 3 sites in United States
- Volunteers
- 152 people
- Sponsor
- Washington University School of Medicine
Charcot Foot, Diabetes Mellitus
The DENOCHARCOT Trial
The aim of the present trial is to assess the efficacy of treatment of acute Charcot foot in diabetes patients with Prolia® on clinical relevant Outcomes in a randomized, double blind, placebo-controlled trial.
- Trial name
- NCT04547348
- Testing
- Denosumab Injection
- Where
- 8 sites in Denmark
- Volunteers
- 38 people
- Sponsor
- Ole Lander Svendsen
Osteoporosis
Preserving Geriatric Muscle With an Osteoporosis Medication
Our goal is to demonstrate efficacy of the novel agent Denosumab to improve or preserve muscle health, strength, mobility and function in frail older adults.
- Trial name
- NCT06118905
- Testing
- Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Infusion
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Chrissy Kistler
Sarcopenia in Elderly
RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis
The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis.
- Trial name
- NCT06643780
- Testing
- Denosumab, Zolendronic Acid
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
Sarcopenia in Elderly
RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients
The objective of this study is to conduct a pragmatic, randomized, double-blind, active-controlled trial to assess the efficacy of receptor activator of nuclear factor-kB ligand (RANKL) inhibition in the treatment of sarcopenia…
- Trial name
- NCT07056478
- Testing
- Denosumab (Prolia), Zoledronic acide (Aclasta)
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
NSCLC, Stereotactic Body Radiation Therapy (SBRT)
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
Introduction: Immunotherapy in combination with chemotherapy have been recommended as the first-line treatment of driver-negative advanced non-small cell lung cancer (NSCLC), but the efficacy is worse in NSCLC patients with bone…
- Conditions
- NSCLC, Stereotactic Body Radiation Therapy (SBRT), Immunotherapy
- Trial name
- NCT06738160
- Testing
- Narlumosbart, Stereotactic Body Radiation Therapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Fudan University
Postmenopausal Osteoporosis, Low Bone Mass
Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass
This is a randomized, double-blind, placebo- and active-controlled Phase II study evaluating the efficacy and safety of TST002 injection (a humanized monoclonal antibody) in postmenopausal women with osteoporosis or low bone…
- Trial name
- NCT07806331
- Testing
- Denosumab
- Volunteers
- 110 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Completed, with results posted
All 101Sarcopenia, Osteoporosis
Muscle Impact of Treating Osteoporosis
Osteosarcopenia is a geriatric musculoskeletal syndrome characterized by co-existence of osteoporosis and sarcopenia (low skeletal muscle mass, strength, and/or functional capacity).
- Trial name
- MITO (NCT05666310)
- Testing
- Denosumab, Zoledronic Acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nami Safai Haeri
Osteoporosis, Postmenopausal
A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis
The purpose of this study is to demonstrate similar efficacy and safety between TVB-009 and Prolia® (denosumab)
- Trial name
- NCT04729621
- Testing
- TVB-009, Prolia®
- Where
- 78 sites in United States, Bulgaria and 8 more
- Volunteers
- 332 people
- Sponsor
- Teva Pharmaceuticals USA
Smoldering Multiple Myeloma
Denosumab for Smoldering Multiple Myeloma
This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.
- Trial name
- NCT03839459
- Testing
- Denosumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Rochester
Osteoporosis
Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study
Investigators will test the hypothesis that an increase in bone turnover markers (e.g. carboxy-terminal collagen crosslinks (CTX) and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who…
- Trial name
- NCT04177940
- Testing
- DMAB Discontinuation and Switching
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Alabama at Birmingham
Melanoma Stage Iii, Melanoma Stage Iv
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
This is a multicenter open-label, single-arm, phase II study designed to investigate the pharmacodynamic and antitumor effects of denosumab alone and in combination with an anti-Programmed death-1 or Programmed death ligand 1…
- Conditions
- Melanoma Stage Iii, Melanoma Stage Iv, Melanoma, Melanoma (Skin)
- Trial name
- NCT03620019
- Testing
- Denosumab, Pembrolizumab, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center